This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

eReport

Collaborating With Patients to Make Treatment Decisions Based on Benefits and Risks of Medications Associated With Tardive Dyskinesia

Andrew A. Nierenberg, MD

Published: November 3, 2020

This CME activity is expired. For more CME activities, visit CMEInstitute.com.
Find more articles on this and other psychiatry and CNS topics:
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

 

Abstract

Many patients who are at risk for tardive dyskinesia fear that they might develop the involuntary neurological movement disorder, yet it is possible for clinicians to convey a realistic assessment of the benefits and risks of medications that might induce TD. Clinicians need to be aware of the importance of communicating reasonable risk in a way that will not alarm patients, using tools such as probabilities and phronesis in discussions with their patients.

J Clin Psychiatry 2020;81(6):NU19047BR2C


Volume: 81

Quick Links: Movement Disorders

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Young-Adult Social Outcomes of Attention-Deficit/Hyperactivity Disorder

ADHD that persisted into young-adulthood was associated with poorer outcomes in terms of education, employment, and emotional...

Read More...